DalCor Pharmaceuticals is a pioneering biopharmaceutical company that is focused on addressing cardiovascular disease, which is currently the greatest global healthcare burden. Their goal is to deliver dalcetrapib, the first pharmacogenomic precision medicine in cardiovascular disease, specifically targeting patients with the ADCY9 AA genotype. Currently, dalcetrapib is being evaluated in the dal-GenE Phase 3 cardiovascular clinical outcomes trial, with the aim of reducing major adverse cardiovascular events (MACE).

The trial is expected to be completed in the first half of 2021, following a successful futility analysis in January 2020. Dalcetrapib has already been administered to over 10,000 patients with cardiovascular diseases and risk factors, such as obesity, diabetes, and hypertension, with a good safety and tolerability profile. A companion diagnostic test, developed in collaboration with Roche Molecular Systems, identifies patients with the ADCY9 AA genotype who may benefit from dalcetrapib treatment.

DalCor has obtained exclusive global rights to develop, manufacture, and commercialize dalcetrapib through at least 2034, making them a leader in precision medicine for cardiovascular diseases